Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histological confirmed and documented diagnosis of non-muscle invasive urothelial carcinoma
•Participants with recurrent non-muscle invasive bladder cancer (intermediate risk or high risk)
•Ineligible for or elected not to undergo radical cystectomy
•No evidence of upper tract urothelial cancer or cancer within the prostatic urethra as documented by imaging studies performed within 6 months of enrollment
•Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
•Adequate bone marrow, renal and liver function

•Evidence of muscle-invasive, locally advanced or metastatic urothelial carcinoma or concurrent extravesical, non-muscle invasive urothelial carcinoma
•Macroscopic hematuria, traumatic catheterization or active urinary tract infection
•Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent
•Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) Hepatitis B, Hepatitis C, and known Human Immunodeficiency Virus infection or Acquired Immunodeficiency Syndrome-related illness

Related studies

NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more

NCT07206225 · Non-muscle Invasive Bladder Cancer

NCT06770582 · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, and more

NCT03317158 · Urothelial Carcinoma, Bladder Cancer

NCT06253871 · HER2 Mutation-Related Tumors, HER2, and more

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)